We are pleased to announce that our CEO, Alexander Seyf, was recently featured in The Pharma Navigator’s latest deep dive into the evolution of cell and gene therapies.

As the industry moves from research breakthroughs to commercial reality, Alexander joined other global experts to discuss how we can overcome the “complexity hurdle” inherent in next-generation medicine.

Key takeaways include:

👉 Moving beyond traditional pharmaceuticals means demonstrating robust traceability and consistency across the entire lifecycle, from raw materials to final release.

👉 Many early-stage workflows rely on manual processes that hinder large-scale production. Transitioning away from these is essential to reducing quality inconsistencies and protracted timelines.

👉 Automation and digitization are critical for diminishing the reliance on manual steps. Real-time data capture and electronic batch records (EBR) allow for faster, more informed decision-making.

👉 Technologies like closed-system manufacturing and modular facilities are key to increasing capacity and accelerating the transfer of life-saving therapies across borders.

“Automation and digitization are diminishing the need for manual steps and specialized personnel, leading to improved scalability and consistent batch quality.” – Alexander Seyf

Read the full article here.